title: [The management of systemic lupus erythematosus with biological therapies].
abstract: The efficacy and safety of targeted biological therapies have been analyzed in patients suffering from systemic lupus erythematosus. In renal lupus, infliximab has shown prolonged improvement of the renal function after the induction period (small open studies), whereas abatacept had no significant efficacy (randomised controlled study). In renal and non renal lupus, rituximab did not confirm its efficacy in two randomised controlled studies. In non renal lupus, epratuzumab has shown efficacy in a phase IIb. Belimumab at the high posology of 10 mg/kg has also shown significant efficacy in two large randomised controlled studies.
authors.affiliation: Service de rhumatologie, CHU de Liege, Sart Tilman, 4000 Liège, Belgique. michel.malaise@ulg.ac.be
authors.forename: O
authors.initials: O
authors.lastname: Malaise
authors.forename: C
authors.initials: C
authors.lastname: von Frenckell
authors.forename: B
authors.initials: B
authors.lastname: André
authors.forename: M G
authors.initials: MG
authors.lastname: Malaise
mesh_terms: D000069594:Abatacept; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; C448700:epratuzumab; C511911:belimumab; D000069594:Abatacept; D000069285:Infliximab